Worksite-based intensive lifestyle therapy has profound cardiometabolic benefits in people with obesity and type 2 diabetes.
Worksite-based intensive lifestyle therapy has profound cardiometabolic benefits in people with obesity and type 2 diabetes.
复制标题
DOI:
10.1016/j.cmet.2022.08.012
复制
发表时间:
2022-10-04
期刊:
影响因子:
29
通讯作者:
Klein, Samuel
中科院分区:
文献类型:
--
作者:
Yoshino, Mihoko;Yoshino, Jun;Smith, Gordon I.;Stein, Richard I.;Bittel, Adam J.;Bittel, Daniel C.;Reeds, Dominic N.;Sinacore, David R.;Cade, W. Todd;Patterson, Bruce W.;Cho, Kevin;Patti, Gary J.;Mittendorfer, Bettina;Klein, Samuel
Lifestyle therapy (energy-restriction and exercise) is the cornerstone of therapy for people with type 2 diabetes (T2D) but is difficult to implement. We conducted an 8-month randomized controlled trial in persons with obesity and T2D (17 women and 1 man) to determine the therapeutic effects and potential mechanisms of intensive lifestyle therapy on cardiometabolic function. Intensive lifestyle therapy was conducted at the worksite to enhance compliance and resulted in marked (17%) weight loss, and beneficial changes in body fat mass, intrahepatic triglyceride content, cardiorespiratory fitness, muscle strength, glycemic control, β-cell function and multi-organ insulin sensitivity, which were associated with changes in muscle NAD+ biosynthesis, sirtuin signaling, and mitochondrial function and in adipose tissue remodeling. These findings demonstrate that intensive lifestyle therapy provided at the worksite has profound therapeutic clinical and physiological effects in people with T2D, that are likely mediated by specific alterations in skeletal muscle and adipose tissue biology. ⦁ Mihoko et al. report that intensive lifestyle therapy provided at the worksite causes marked weight loss, increased cardiorespiratory fitness and muscle strength, and improved physiological factors involved in the pathogenesis of T2D (β-cell function, multi-organ insulin sensitivity, and skeletal muscle/adipose tissue biology) in people with obesity and type 2 diabetes
登录
查看更多内容
影响因子:
13.6
作者:
Kim Y;White T;Wijndaele K;Westgate K;Sharp SJ;Helge JW;Wareham NJ;Brage S
通讯作者:
Brage S
影响因子:
29
作者:
Klein S;Gastaldelli A;Yki-Järvinen H;Scherer PE
通讯作者:
Scherer PE
影响因子:
5.6
作者:
Koh HE;Cao C;Mittendorfer B
通讯作者:
Mittendorfer B
影响因子:
7.7
作者:
Gastaldelli, Amalia;Abdul Ghani, Muhammad;DeFronzo, Ralph A.
通讯作者:
DeFronzo, Ralph A.
影响因子:
5.3
作者:
Khan, Tayeba;Muise, Eric S.;Scherer, Philipp E.
通讯作者:
Scherer, Philipp E.